Platelet activation and aggregation at sites of vessel wall injury is crucial to prevent posttraumatic blood loss, but it also causes precipitate diseases such as myocardial infarction and stroke, which are still leading causes of death and disability in industrialized countries ( 1 ) . Inhibition of platelet function is an important strategy for the prevention and treatment of myocardial infarction ( 2 ) and, possibly, stroke ( 2, 3 ) . Platelet activation is triggered by subendothelial collagens, thromboxane A 2 (TxA 2 ) and ADP released from activated platelets, and thrombin generated by the coagulation cascade ( 4 ) . Although these agonists trigger diff erent signaling pathways, all activate phospholipase Cs (PLCs), leading to the production of diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP 3 ). IP 3 induces the release of Ca 2+ from the sarcoplasmatic reticulum (SR), which is thought to trigger the infl ux of extracellular Ca 2+ by a mechanism known as store-operated Ca 2+ entry (SOCE) ( 5, 6 ) . In addition, DAG and some of its metabolites have been shown to induce non-SOCE ( 7 ) . Stromal interaction molecule 1 (STIM1) is an SR/endoplasmic reticulum (ER) -resident protein necessary for the detection of ER Ca 2+ depletion and the activation of SOC channels in T cells ( 8 -10 ) and mast cells ( 11 ) . In human T cells, the four transmembrane -domain protein Orai1 (Ca 2+ release -activated channel modulator) appears to be the predominant SOC channel ( 12 ) , but the C-terminal region of STIM1 also interacts with other SOC channel candidates, such as transient receptor potential channels (TRPCs) 1, 2, and 4 ( 13 ) . In platelets, STIM1 is expressed at high levels ( 14 ) and may Platelet activation and aggregation are essential to limit posttraumatic blood loss at sites of vascular injury but also contributes to arterial thrombosis, leading to myocardial infarction and stroke. Agonist-induced elevation of [Ca 2+ ] i is a central step in platelet activation, but the underlying mechanisms are not fully understood. A major pathway for Ca 2+ entry in nonexcitable cells involves receptor-mediated release of intracellular Ca 2+ stores, followed by activation of store-operated calcium (SOC) channels in the plasma membrane. Stromal interaction molecule 1 (STIM1) has been identifi ed as the Ca 2+ sensor in the endoplasmic reticulum (ER) that activates Ca 2+ release -activated channels in T cells, but its role in mammalian physiology is unknown. Platelets express high levels of STIM1, but its exact function has been elusive, because these cells lack a normal ER and Ca 2+ is stored in a tubular system referred to as the sarcoplasmatic reticulum. We report that mice lacking STIM1 display early postnatal lethality and growth retardation. STIM1-defi cient platelets have a marked defect in agonist-induced Ca 2+ responses, and impaired activation and thrombus formation under fl ow in vitro. Importantly, mice with STIM1-defi cient platelets are signifi cantly protected from arterial thrombosis and ischemic brain infarction but have only a mild bleeding time prolongation. These results establish STIM1 as an important mediator in the pathogenesis of ischemic cardio-and cerebrovascular events.
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Mice heterozygous for the STIM1-null mutation developed normally, whereas a majority ( ‫ف‬ 70%) of mice lacking STIM1 ( Stim1 Ϫ / Ϫ ) died within a few hours after birth. Marked cyanosis was noted before death, suggesting a cardiopulmonary defect. Surviving Stim1 Ϫ / Ϫ mice exhibited marked growth retardation, achieving ‫ف‬ 50% of the weight of wild-type littermates at 3 and 7 wk of age ( Fig. 1, A and B ) . Western blot analyses confi rmed the absence of STIM1 in platelets ( Fig. 1 C ,  top) and other tissues (not depicted). Blood platelet counts ( Fig. 1 D ) , mean platelet volume, and expression levels of major platelet surface receptors, including glycoprotein (GP) Ib-V-IX, GPVI, CD9, and ␤ 1 and ␤ 3 integrins (not depicted) contribute to SOCE by interacting with TRPC1 ( 15 ) . We recently reported that mice expressing an activating EF-hand mutant of STIM1 have elevated [Ca 2+ ] i levels in platelets, macrothrombocytopenia, and a bleeding disorder, indicating a role for STIM1-dependent SOCE in platelet function ( 14 ) . The importance of SOCE for platelet activation, hemostasis, and thrombosis, however, remains unknown, and the mechanisms underlying the process are not defi ned.
RESULTS AND DISCUSSION
To address the function of STIM1 in vivo, the Stim1 gene was disrupted in mice by insertion of an intronic gene trap cassette. low concentrations of these agonists (not depicted). In contrast, responses to collagen and CRP ( Fig. 2 C ) and the strong GPVI agonist convulxin (not depicted) were signifi cantly diminished. The activation defect was confi rmed by fl ow cytometric analysis of integrin ␣ IIb ␤ 3 activation using the JON/A-PE antibody, and of degranulation-dependent P-selectin surface exposure ( Fig. 2 D ) . Therefore, loss of STIM1-dependent SOCE impairs GPVI-induced integrin activation and degranulation, whereas G protein -coupled agonists are still able to induce normal activation in Stim1 Ϫ / Ϫ platelets in these assays, despite the defect in [Ca 2+ ] i signaling.
In vivo, platelet activation on the extracellular matrix or a growing thrombus occurs in fl owing blood, where locally produced soluble mediators are rapidly cleared. Under these conditions, reduced potency of platelet activators may become limiting, particularly at the high fl ow rates found in arteries and arterioles. Therefore, we analyzed the ability of Stim1 Ϫ / Ϫ platelets to form thrombi on collagen-coated surfaces in a wholeblood perfusion system ( 16 ) . Under high shear conditions (1,700 s Ϫ 1 ), wild-type platelets adhered to collagen fi bers and formed aggregates within 2 min that consistently grew into large thrombi by the end of the perfusion period ( Fig. 2 E ) . In sharp contrast, Stim1 Ϫ / Ϫ platelets exhibited reduced adhesion, and three-dimensional growth of thrombi was markedly impaired. As a consequence, the surface area covered by platelets and the total thrombus volume were reduced ‫ف‬ 42 and ‫ف‬ 81%, respectively. Similar results were obtained at intermediate shear rates (1,000 s Ϫ 1 ; not depicted). These fi ndings indicate that STIM1-mediated SOCE is required for effi cient platelet activation on collagen and on the surface of growing thrombi under conditions of high shear.
Unstable arterial thrombi in Stim1 ؊ / ؊ mice Because platelet aggregation may contribute to pathological occlusive thrombus formation, we studied the eff ects of STIM1 defi ciency on ischemia and infarction by in vivo fl uorescence microscopy after ferric chloride -induced mesenteric arteriole injury. In all wild-type chimeras, the formation of small aggregates was observed ‫ف‬ 5 min after injury, with progression to complete vessel occlusion in 8 out of 10 mice within 30 min (mean occlusion time = 16.5 ± 2.8 min; Fig. 3 , A -C ). In contrast, aggregate formation was signifi cantly delayed in ‫ف‬ 50% of the Stim1 Ϫ / Ϫ chimeras (10.6 ± 5.8 min in wild-type and 17.1 ± 7.3 min in Stim1 Ϫ / Ϫ chimeras until the fi rst thrombus > 20 μ m in diameter appeared; P < 0.05), and formation of stable thrombi was almost completely abrogated. This defect was caused by the release of individual platelets from the surface of the thrombi (Videos 1 and 2, available at http://www.jem.org/cgi/content/ full/jem.20080302/DC1) and not by embolization of large thrombus fragments. Blood fl ow was maintained throughout the observation period in 9 out of 10 vessels, demonstrating a crucial role for STIM1 during occlusive thrombus formation. This was confi rmed in a second arterial thrombosis model in which the abdominal aorta was mechanically injured and blood fl ow was monitored with an ultrasonic fl ow probe.
were normal, indicating that STIM1 is not essential for megakaryopoiesis or platelet production. Similarly, no diff erences were found in red blood cell counts, hematocrit, or the activated partial thromboplastin time, a method for the assessment of plasma coagulation ( Table I ) . To determine if STIM1 has a role in platelet SOCE, we induced SOC infl ux in wild-type and Stim1 Ϫ / Ϫ platelets with the SR/ER Ca 2+ ATPase (SERCA) pump inhibitor thapsigargin (TG). Interestingly, TG-induced Ca 2+ store release was reduced ‫ف‬ 60% in Stim1 Ϫ / Ϫ platelets compared with wild-type controls ( Fig. 1 E ) . Furthermore, subsequent TG-dependent SOC infl ux was almost completely absent in Stim1 Ϫ / Ϫ cells ( Fig. 1 E ) . This demonstrates for the fi rst time that STIM1 is essential for SOCE in platelets and suggests that STIM1-dependent processes contribute to the regulation of Ca 2+ store content in these cells.
Defective SOC infl ux in Stim1 ؊ / ؊ platelets Because of the early mortality and pronounced growth retardation in Stim1 Ϫ / Ϫ mice, all subsequent studies were performed with lethally irradiated wild-type mice transplanted with Stim1 Ϫ / Ϫ or wild-type bone marrow. 4 wk after transplantation, platelet counts were normal and STIM1 defi ciency in platelets was confi rmed by Western blotting ( Fig. 1 C , bottom). To determine the signifi cance of defective SOCE for agonist-induced platelet activation, we assessed changes in [Ca 2+ ] i in response to ADP, thrombin, a collagen-related peptide (CRP) that stimulates the collagen receptor GPVI ( Fig. 2 , A and B ), and the TxA 2 analogue U46619 (not depicted). Ca 2+ release from intracellular stores was reduced in Stim1 Ϫ / Ϫ platelets compared with control for all agonists, indicating reduced Ca 2+ levels in stores in Stim1 Ϫ / Ϫ cells. In the presence of extracellular calcium, Ca 2+ infl ux was dramatically reduced in Stim1 Ϫ / Ϫ platelets. Thus, STIM1-dependent SOCE is a crucial component of the Ca 2+ signaling mechanism in platelets for all major agonists, and non-SOCE makes only a minor contribution, at least under the conditions tested.
STIM1 in platelet activation and thrombus formation
To test the functional consequences of this defect, we performed ex vivo aggregation studies. Stim1 Ϫ / Ϫ platelets aggregated normally to the G protein -coupled agonists ADP, thrombin ( Fig. 2 C ) , and U46619 (not depicted), even at very To test whether the defect in Stim1 Ϫ / Ϫ platelets impaired hemostasis, we measured tail bleeding times. Although bleeding stopped in 28 out of 30 (93.3%) control mice within 10 min, bleeding was highly variable in Stim1 Ϫ / Ϫ chimeras, with 11 out of 31 (35.5%) mice bleeding for > 10 min (P < 0.02; Fig. 3 F ) . These results show that STIM1 is required for normal hemostasis.
STIM1 is an essential mediator of ischemic brain infarction
Ischemic stroke is the third leading cause of death and disability in industrialized countries ( 17 ) . Although it is well established that microvascular integrity is disturbed during cerebral ischemia ( 18 ) , the signaling cascades involved in intravascular thrombus formation in the brain are poorly understood. To determine the importance of STIM1-dependent SOCE in this process, we studied the development of neuronal damage in Stim1 Ϫ / Ϫ chimeras after transient cerebral ischemia in a model that depends on thrombus formation in microvessels downstream from a middle cerebral artery (MCA) occlusion ( 19 ) . To initiate transient cerebral ischemia, a thread was advanced through the carotid artery into the MCA and allowed to remain for 1 h (transient MCA occlusion [tMCAO]), reducing regional cerebral fl ow by > 90% ( 3 ). In Stim1 Ϫ / Ϫ chimeras, infarct volumes 24 h after reperfusion, as assessed by 2,3,5-triphenyltetrazolium chloride (TTC) staining, were reduced to < 30% of the infarct volumes in control chimeras (17 ± 4.4 vs. 62.9 ± 19.3 mm 3 ; P < 0.0001; Fig. 4 A ) . Reductions in infarct size were functionally relevant, as the Bederson score assessing global neurological function (1.86 ± 0.48 vs. 3.07 ± 0.35, respectively; P < 0.0001) and the grip test, which specifi cally measures motor function and coordination (3.71 ± 0.39 vs. 2 ± 0.65, respectively; P < 0.0001), were signifi cantly better in Stim1 Ϫ / Ϫ chimeras compared with controls ( Fig. 4, B and C ) . Serial magnetic resonance imaging (MRI) on living mice was used to confi rm the protective eff ect of STIM1 defi ciency on infarct development. Hyperintense ischemic infarcts on T2-weighted (T2-w) MRI 
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Moreover, no intracranial hemorrhage was detected on T2-w gradient echo images, a highly sensitive MRI sequence for the detection of blood ( Fig. 4 D ) , indicating that STIM1 defi ciency in hematopoietic cells is not associated with an increase in in Stim1 Ϫ / Ϫ chimeras were < 10% of the size of infarcts in control chimeras 24 h after tMCAO (P < 0.0001; Fig. 4 D ) . Importantly, infarct volume did not increase between days 1 and 7, indicating a sustained protective eff ect for STIM1 defi ciency. bleeding complications in the brain. Consistent with the TTC stains and MRI images, histological analysis revealed massive ischemic infarction of the basal ganglia and neocortex in control chimeras but only limited infarction of the basal ganglia in Stim1 Ϫ / Ϫ chimeras ( Fig. 4 E ) . The density of CD3 + T cell and monocyte/macrophage infi ltrates in brain infarcts was low, and did not diff er between Stim1 Ϫ / Ϫ and control chimeras at 24 h (not depicted).
STIM1 has been identifi ed as the long-sought calcium sensor that connects intracellular Ca 2+ store depletion to the activation of plasma membrane SOC channels in immune cells. Although SOCE is thought to be a major pathway of Ca 2+ entry in virtually all nonexcitable cells, this has only been directly shown for T cells ( 8 -10 ) and IgE-dependent mast cell activation ( 11 ) . Although STIM1 is highly expressed in platelets ( 14 ) , the signifi cance of SOCE for platelet function has been unknown because non-SOCE pathways have been described to exist in these cells ( 20 ) . We found severely defective Ca 2+ responses to all major agonists in Stim1 Ϫ / Ϫ platelets, clearly establishing SOCE as the major route of Ca 2+ entry in those cells and STIM1 as an essential mediator of this process. The residual Ca 2+ infl ux detected in the mutant cells suggests that other molecules may regulate SOC infl ux, but only to a minor extent. One candidate molecule is STIM2, which has been shown to activate Ca 2+ release -activated channels ( 21 ) . Alternatively, the residual Ca 2+ entry could be mediated by store-independent mechanisms as DAG, and some of its metabolites have been shown to induce non-SOCE ( 7 ). In line with this, members of the TRPC family have been suggested as candidates mediating both SOCE and non-SOCE in platelets ( 15, 20 ) .
Besides the severely impaired SOCE, we also observed reduced Ca 2+ release from intracellular stores upon agonistinduced platelet activation, which likely refl ects a lower fi lling state of the SR, as shown by passively emptying the stores with the SERCA inhibitor TG ( Fig. 1 E ) . Similar observations have very recently been reported in mast cells ( 11 ) , indicating that STIM1 may be involved in the fi lling of intracellular Ca 2+ stores. However, mast cells lacking the major SOC channel Orai1 ( 22 ) show normal store content, suggesting a SOC channel -independent role of STIM1 in store refi ll, possibly through interaction with the IP 3 receptors or SERCA pumps in the SR/ER. Because platelets do not have a normal ER, an interesting question is where STIM1 is located in these cells. The major intracellular Ca 2+ store seems to be in the so-called dense tubular system, an equivalent of the ER in megakaryocytes. However, lysosome-related (acidic) organelles have been proposed as a second source of intracellularly stored Ca 2+ in platelets. Further studies are required to clarify the exact location of STIM1 in platelets. under fl ow but is not required for the activation and aggregation of platelets in the absence of shear forces ( 1, 25 ) .
Our data indicate that STIM1-dependent SOCE may be of greater relevance for arterial occlusive thrombus formation than for primary hemostasis, though prolonged tail bleeding was observed in a subgroup of Stim1 Ϫ / Ϫ chimeras ( Fig. 3 ) . This raises the interesting possibility that hemostasis and thrombosis are mechanistically distinct processes. Therefore, the identifi cation of the mechanisms that trigger pathological thrombus formation but are less essential to arrest bleeding may be the key to the development of safe antithrombotics. This will be of particular importance for the treatment of acute stroke, which is still the third leading cause of death and disability in industrialized countries, with very limited treatment options ( 17 ) . Numerous attempts to attenuate infarct progression in acute stroke patients by conventional platelet aggregation inhibitors or anticoagulation failed because of an excess of intracerebral hemorrhages ( 26 ) . We found that Stim1 Ϫ / Ϫ chimeras are protected from neuronal damage after transient cerebral ischemia without displaying an increased risk of intracranial hemorrhage ( Fig. 4 ) despite prolonged tail bleeding times observed in a subgroup of the animals, which confi rms that there is no clear correlation between bleeding time and risk ( 27 ) . These fi ndings are in line with our recent observation that inhibition of the GPIb -GPVI axis is protective in this model, whereas integrin ␣ IIb ␤ 3 (GPIIb/IIIa) inhibition is not but is associated with excess intracranial bleeding ( 3 ), which corresponds well with data from clinical studies in stroke patients ( 26 ) . It is important to note, however, that data obtained in the mouse tMCAO model cannot be directly extrapolated to the human situation, as diff erences in the pathomechanisms may exist.
Overall, the phenotype of mice with Stim1 Ϫ / Ϫ platelets is similar to that of mice lacking functional GPVI or mice treated with antibodies that block the von Willebrand factor binding site on GPIb ␣ , which show severe defects in thrombus formation under fl ow, protection from arterial thrombus formation, and ischemic brain damage, but which only exhibit a limited risk for bleeding complications ( 3, 28 ) . This supports the notion that SOCE is particularly important for GPIb -GPVI -ITAM signaling pathways in platelets, which is in line with the well-documented function of STIM1 in ITAM signaling in T cells and mast cells ( 10, 22 ) .
Collectively, the results presented in this paper establish STIM1 as an essential mediator of platelet activation that is of critical importance during arterial thrombosis and ischemic brain infarction but not normal hemostasis. These fi ndings may open the way for the development of novel highly eff ective and safe antithrombotics.
MATERIALS AND METHODS
Mice. Animal studies were approved by the district government of Lower Franconia (Bezirksregierung Unterfranken). The generation of Stim1 Ϫ / Ϫ mice was as follows. A gene trap embryonic stem (ES) cell line containing an insertional disruption in the Stim1 gene (RRS558; clone no. IRAKp961K1818Q; imaGenes) was purchased from BayGenomics. Male chimeras from this ES cell line were bred to C57BL/6 females to generate Stim1 +/ Ϫ mice, Although STIM1 defi ciency severely reduced Ca 2+ entry in platelets in response to all agonists tested, it did not impair G protein -coupled receptor (GPCR)/PLC ␤ Ϫ triggered integrin ␣ IIb ␤ 3 activation or release of granule content in the absence of fl ow ( Fig. 2 ) , even at very low agonist concentrations (not depicted). This shows that SOCE is not essential for these processes when the agonist can act on the cells at constant concentrations for a prolonged period of time. In contrast, GPVI/PLC ␥ 2-induced cellular activation was impaired under these experimental conditions, even at very high agonist concentrations ( Fig. 2 C ) . The reason for this is not clear at present, but it could be related to the fact that GPVI and GPCRs activate diff erent PLC isoforms in platelets. GPVI ligation triggers tyrosine phosphorylation cascades downstream of the receptor-associated immunoreceptor tyrosine-based activation motif (ITAM), culminating in the activation of PLC ␥ 2 ( 23 ), whereas soluble agonists such as thrombin, ADP, and TxA 2 stimulate receptors that couple to heterotrimeric G proteins (Gq) and lead to activation of PLC ␤ ( 24 ). Our Ca 2+ measurements show that store release and subsequent SOC infl ux occur signifi cantly faster upon Gq/PLC ␤ stimulation compared with GPVI/PLC ␥ 2 stimulation ( Fig. 2 A ) , suggesting diff erent kinetics of IP 3 production between these two pathways that could infl uence subsequent events. Clearly, the low [Ca 2+ ] i levels alone cannot explain the defective activation downstream of GPVI/PLC ␥ 2, as similar or lower levels are seen in response to thrombin and ADP, respectively, without causing this defect. Possibly, elevated [Ca 2+ ] i levels have to act in concert with other transient signals, which may not or no longer be fully present in GPVI/PLC ␥ 2-stimulated Stim1 Ϫ / Ϫ platelets. This could also explain why platelets expressing an activating EF-hand mutant of STIM1 that leads to elevated basal [Ca 2+ ] i levels display a selective GPVI/PLC ␥ 2 signaling defect, whereas Gq/PLC ␤ -induced store release and Ca 2+ entry are largely preserved ( 14 ) .
The rather moderate activation defi cits seen in Stim1 Ϫ / Ϫ platelets in the absence of fl ow translated into severely defective formation of stable three-dimensional thrombi under conditions of medium and high shear ( Fig. 3 ) . Such a phenotype has previously been reported in several mice with deficiencies in platelet proteins, including those lacking the heterotrimeric G protein subunit G 13 or CD40 ligand, which display marked defects in thrombus stability under fl ow in vitro and in vivo despite only mild defects in activation/aggregation in the absence of fl ow (for review see reference 4 ). This suggests that STIM1-dependent SOCE is particularly important under conditions where agonist potency becomes limiting because of rapid dilution and various stimuli have to be integrated to produce an appropriate cellular response ( 24 ) . Reduced exposure times rather than low concentrations of these soluble agonists appear to cause the defect under fl ow, as we observed no reduction in the aggregation response to GPCR activation in Stim1 Ϫ / Ϫ platelets, even at very low agonist concentrations (not depicted). In addition, STIM1 may be involved in the generation of Ca 2+ signals downstream of GPIb, which is essential for adhesion and thrombus formation which were intercrossed to produce Stim1 Ϫ / Ϫ mice. In the ES cells, the gene trap vector pCMV-SPORT6, which is composed of a splice-acceptor site followed by a " ␤ Geo " cassette encoding a fusion of ␤ -galactosidase and neomycin phosphotransferase II, was inserted 600 bp downstream of exon 7, into intron 7 of the Stim1 gene. The integration site was confi rmed by PCR and sequencing of the amplifi ed genomic DNA fragment using exon 7 forward (5 Ј -gctgcacaaggcccaggagg-3 Ј ) and geo1 reverse (5 Ј -atcggcctcaggaagatcgc-3 Ј ) primers. The transcript would result in the generation of a fusion protein between truncated Stim1 (extracellular region plus transmembrane domain) and ␤ -galactosidase. This fusion protein was, however, not detectable in platelets by Western blotting using anti -␤ -galactosidase antibodies or anti-STIM1 antibodies that recognize the N terminus of the protein (GOK/Stim1, clone 44; BD Bioscience) ( 11 ) , suggesting that it is rapidly degraded. For the generation of bone marrow chimeras, 5 -6-wkold C57BL/6 female mice were lethally irradiated with a single dose of 10 Gy, and bone marrow cells from 6-wk-old wild-type or Stim1 Ϫ / Ϫ mice were injected intravenously into the irradiated mice (4 × 10 6 cells per mouse). 4 wk after transplant, platelet counts were determined and STIM1 defi ciency was confi rmed by Western blotting. All recipient animals received acidifi ed water containing 2 g/liter neomycin sulfate for 6 wk after transplantation.
Chemicals and antibodies.
Anesthetic drugs used included medetomidine (Pfi zer), midazolam (Roche), and fentanyl (Janssen-Cilag GmbH). For antagonists, atipamezol (Pfi zer) and fl umazenil and naloxon (both purchased from Delta Select GmbH) were used according to local authority regulations. ADP (Sigma-Aldrich), U46619 (Qbiogene), thrombin (Roche), collagen (Kollagenreagent Horm; Nycomed), and TG (Invitrogen) were purchased as indicated. Monoclonal antibodies conjugated to FITC or PE, or DyLight 488 were obtained from Emfret Analytics. The JON/A-PE antibody preferentially binds to the high affi nity conformation of mouse integrin ␣ IIb ␤ 3 (Emfret Analytics). Anti-STIM1 monoclonal antibodies were purchased from BD Biosciences (GOK/Stim1, clone 44) and Abnova (clone 5A2).
Intracellular calcium measurements.
Platelet intracellular calcium measurements were performed as previously described ( 29 ) . In brief, platelets isolated from blood were washed, suspended in Tyrode ' s buff er without calcium, and loaded with 5 μ M Fura-2/AM in the presence of 0.2 μ g/ml Pluronic F-127 (Invitrogen) for 30 min at 37 ° C. After labeling, platelets were washed once and resuspended in Tyrode ' s buff er containing 0.5 mM Ca 2+ or 1 mM EGTA. Stirred platelets were activated with agonists, and fl uorescence was measured with a fl uorimeter (LS 55; PerkinElmer). Excitation was alternated between 340 and 380 nm, and emission was measured at 509 nm. Each measurement was calibrated using Triton X-100 and EGTA.
Platelet aggregation and fl ow cytometry. Washed platelets (200 μ l with 0.5 × 10 6 platelets/ μ l) were analyzed in the presence of 70 μ g/ml human fibrinogen. Transmission was recorded on a four-channel aggregometer (Fibrintimer; APACT) for 10 minutes and was expressed in arbitrary units, with buff er representing 100% transmission. For fl ow cytometry, heparinized whole blood was diluted 1:20 and incubated with the appropriate fl uorophore-conjugated monoclonal antibodies for 15 min at room temperature and analyzed on a FACSCalibur (Becton Dickinson).
Adhesion under fl ow conditions. Rectangular coverslips (24 × 60 mm) were coated with 0.2 mg/ml fi brillar type I collagen (Nycomed) for 1 h at 37 ° C and blocked with 1% BSA. Heparinized whole blood was labeled with a DyLight 488 -conjugated anti-GPIX Ig derivative at 0.2 μ g/ml, and perfusion was performed as previously described ( 16 ) . Image analysis was performed off -line using Metavue software (Visitron). Thrombus formation was expressed as the mean percentage of total area covered by thrombi, and as the mean integrated fl uorescence intensity per square millimeter.
Bleeding time.
Mice were anesthetized and a 3-mm segment of the tail tip was removed with a scalpel. Tail bleeding was monitored by gently absorbing blood with fi lter paper at 20-s intervals without making contact with the
